ZBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Zenas BioPharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$26.71+1.87 (+7.53%)
Close on Oct 19, 2026
- Market cap
- $1.69B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.76 (+11.52%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Zenas BioPharma, Inc. grew revenue 100.0% to $10.00M over fiscal 2025. Free cash flow was -$225.97M.
Revenue
$10.00M
+100.0% vs. a year earlier
Operating income
-$475.57M
TTM Q2 2026
Free cash flow
-$225.97M
TTM Q2 2026
EPS, diluted
-$8.98
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $1.69B
- P/E ratio
- –
- Price to sales
- 168.57
- Price to book
- 6.82
- Dividend yield
- –
- Free cash flow yield
- -13.41%
Fundamentals
- Revenue
- $10.00M
- Net income
- -$484.38M
- EPS, diluted
- -$8.98
- Free cash flow
- -$225.97M
- Book value per share
- $3.92
- Diluted shares
- 63M
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$475.57M
Net income
-$484.38M
EPS, diluted
-$8.98
Free cash flow
-$225.97M
Reported periodTrailing twelve months